MindMed Keynote

In the past five years psychiatry has seen greater innovation than in the previous five decades, with psychedelic medicines set to transform the lives of millions of patients worldwide. As clinical studies demonstrate treatment safety and efficacy, they instigate regulatory reform and the creation of a global industry expected to exceed £1.5 billion by 2026.

MindMed’s Chief Executive Officer, Robert Barrow, outlines the importance of expediting patient access to psychedelic healthcare in Europe.